CoronaVac
COVID-19 Prevention
Key Facts
About Sinovac Biotech
Sinovac Biotech's mission is to supply vaccines to eliminate human infectious diseases worldwide. Its key achievement was the development and global distribution of CoronaVac, one of the most widely administered COVID-19 vaccines, which solidified its international standing and showcased its integrated manufacturing model. The company's strategy is anchored in its core inactivated vaccine technology platform, with a focus on expanding its pipeline for both endemic and pandemic threats while pursuing commercial partnerships in emerging markets. Financially, it faces the challenge of transitioning from peak pandemic revenue to a sustainable portfolio-driven growth model.
View full company profileTherapeutic Areas
Other COVID-19 Prevention Drugs
| Drug | Company | Phase |
|---|---|---|
| Intranasal COVID Vaccine | Virpax Pharmaceuticals | Research |
| COVID-19 Vaccine Trials | DM Clinical Research | Not Specified |
| SARS-CoV-2 Vaccine | Epygen Biotech | Not Disclosed |
| IRT Platform (e.g., COVID-19) | Biological Mimetics | Research/Pre-clinical |
| COMIRNATY® (BNT162b2) | Fosun Pharma | Approved |
| BBIBP-CorV | Sinopharm | Approved |
| Recombinant Protein COVID-19 Vaccine | Sinopharm | Approved |
| COVID-19 mRNA Vaccine (SYS6006) | CSPC Innovation Pharmaceutical | Marketed |
| Recombinant COVID-19 Vaccine (CHO Cell) | Zhifei Biological Products | Marketed |
| SARS-CoV-2 Inactivated Vaccine | Hualan Biological Engineering | Marketed |